← Back to Clinical Trials
Recruiting NCT07220876

NCT07220876 Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07220876
Status Recruiting
Phase
Sponsor Avisi Technologies Inc.
Condition Open Angle Glaucoma (OAG)
Study Type INTERVENTIONAL
Enrollment 165 participants
Start Date 2025-11-07
Primary Completion 2027-10

Eligibility & Interventions

Sex All sexes
Min Age 45 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
VisiPlate Glaucoma Implant

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 165 participants in total. It began in 2025-11-07 with a primary completion date of 2027-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial

Eligibility Criteria

Inclusion Criteria: * Open angle, pseudoexfoliative or pigmentary glaucoma * IOP at preoperative visit of ≥ 20mmHg and ≤ 40mmHg * Visual field mean deviation score of -3dB or worse * Area of healthy, free and mobile conjunctiva in the target quadrant * Shaffer angle grade ≥ 2 in the target quadrant Exclusion Criteria: * Angle closure glaucoma * Congenital, neovascular or other secondary glaucomas * Previous intraocular surgery, with the exception of uncomplicated cataract surgery * Previous glaucoma shunt/valve in the target quadrant * Clinically significant inflammation or infection in the study eye within 30 days prior to the operative visit * History of corneal surgery, corneal opacities or corneal disease * Retinal or optic nerve disorders, either degenerative or evolutive, that are not associated with the existing glaucoma condition

Contact & Investigator

Central Contact

Katherine Lee

✉ kati@avisitech.com

📞 12816100251

Frequently Asked Questions

Who can join the NCT07220876 clinical trial?

This trial is open to participants of all sexes, aged 45 Years or older, studying Open Angle Glaucoma (OAG). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07220876 currently recruiting?

Yes, NCT07220876 is actively recruiting participants. Contact the research team at kati@avisitech.com for enrollment information.

Where is the NCT07220876 trial being conducted?

This trial is being conducted at Glendale, United States, Sacramento, United States, Grand Junction, United States, Sheridan, United States and 8 additional locations.

Who is sponsoring the NCT07220876 clinical trial?

NCT07220876 is sponsored by Avisi Technologies Inc.. The trial plans to enroll 165 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology